Finance Watch: BIO Report Shows Record VC Funding Across Geographies

Private Company Edition: Venture capital for emerging therapeutics companies in the US and in ex-US regions reached all-time highs in 2018. Also, Alphamab raises $60m Series B, three new VC funds launch and FLX changes its name to RAPT.

The Biotechnology Innovation Organization (BIO) released new data on financings for emerging therapeutic companies that shows record levels of venture capital investment – not just in the US, but globally.

BIO's 2019 Emerging Therapeutic Company Trend Report defines emerging therapeutics firms as companies with a lead drug in the research...